Tidal Creek Equilibrium: Barataria Bay

Louisiana’s wetlands are losing land in response to sea level changes, anthropogenic influences and natural marine processes. Historical satellite image analysis reveals that between 2005 and 2015, fifteen tidal creeks in Barataria Bay, Louisiana eroded at the rate of 1.80 m/yr (± 1.98 m), and the open water area behind these creeks enlarged at the rate of 530.00 m2/yr (± 204.80 m2). This research revealed that selected tidal creeks within the estuary have cross-sectional areas larger (2639% larger) than established ocean-inlet equilibrium models would predict. This work suggests that tidal prism to tidal creek cross-sectional area relationships in Barataria Bay are most strongly shaped by creek exposure to waves and secondarily by tide range and currents. A trend of increased inlet erosion rates due to large fetch distances is evident, but impacts from storm driven subtidal variations also play an important role

Tidal Creek Equilibrium: Barataria Bay

Louisiana’s wetlands are losing land in response to sea level changes, anthropogenic influences and natural marine processes. Historical satellite image analysis reveals that between 2005 and 2015, fifteen tidal creeks in Barataria Bay, Louisiana eroded at the rate of 1.80 m/yr (± 1.98 m), and the open water area behind these creeks enlarged at the rate of 530.00 m2/yr (± 204.80 m2). This research revealed that selected tidal creeks within the estuary have cross-sectional areas larger (2639% larger) than established ocean-inlet equilibrium models would predict. This work suggests that tidal prism to tidal creek cross-sectional area relationships in Barataria Bay are most strongly shaped by creek exposure to waves and secondarily by tide range and currents. A trend of increased inlet erosion rates due to large fetch distances is evident, but impacts from storm driven subtidal variations also play an important role

Is the Gans Maneuver effective in reducing symptoms of vertigo in patients diagnosed with PC-BPPV?

OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is the Gans Maneuver effective in reducing symptoms of vertigo in patients diagnosed with PC-BPPV?” STUDY DESIGN: Review of three peer-review journal published, single-blinded randomized controlled trials all in the English language with human subjects on patients with PC-BPPV. DATA SOURCES: The three randomized controlled trials that were utilized for this review were found using PubMed, Cochrane Collaboration & Google Scholar. Articles were selected based on relevance to the proposed clinical question and the inclusion of outcomes with evidence that matters to these patients. OUTCOME(S) MEASURED: All of the articles selected measured the subjective absence of vertigo symptoms using some variation of a clinical tool after performing the Gans maneuver. RESULTS: Badawy et al. compared the Gans maneuver with post-therapeutic restrictions to a Canalith repositioning maneuver (modified Epley maneuver with post-therapeutic restrictions). Saberi et al. compared the Gans maneuver to the modified Epley maneuver. Muragod et al. compared the Gans maneuver to the Epley maneuver. All of the studies researched showed a statistically significant reduction in vertigo symptoms after receiving the Gans maneuver. Badawy et al. demonstrated that the reduction of vertigo symptoms over 1 month was an average of 9 out of 10 for the Gans maneuver with PTR when compared to the canalith repositioning maneuver (modified Epley with PTR) at 8 out of 10 change from baseline. Saberi et al. demonstrated that the average percentage of patients with subjective resolution of vertigo symptoms was 46.7% for the Gans maneuver and 70% for the modified Epley maneuver. Muragod et al. demonstrated that the average point change from baseline out of 100 on the DHI was 42.9 for the Gans maneuver and 44.9 for the Epley maneuver. CONCLUSIONS: The data presented by these three single-blinded RCTs suggests that the Gans maneuver is an effective alternative treatment for patients with PC-BPPV in reducing symptoms of vertigo. Future research is warranted with a larger sample size on the adverse side effects & relapse of symptoms for the Epley vs Gans maneuver

Incorporating follicle stimulating hormone to stimulate multiple corpora lutea for embryo transfer in beef cattle

Assisted reproductive technologies, such as estrus synchronization and embryo transfer, can aid producers in improving genetics by increasing the number of progeny produced from elite females. The success of embryo transfer is dependent on a viable, competent embryo and a recipient with a receptive uterine environment. Follicular development and luteinization are pertinent for the recipient to establish a functional corpus luteum (CL) that can produce adequate concentrations of progesterone (P4) and provide a uterine environment conducive for the establishment of pregnancy. The objective of this study was to determine if exogenous follicle stimulating hormone (FSH), would increase the number of CL, size and blood perfusion of the largest CL, as well as circulatory concentrations of P4

Extended treatment with MY-NEOVAX, personalized neoantigen-enhanced oncolytic viruses, for two end-stage cancer patients.

Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical testing with modest reported antitumor effects [ 1]. The less-than-expected activity of these neoantigenic vaccines may correspond with the development of immune escape mechanisms. One permutation on neoantigen vaccines, which may counter or prevent these adaptive immune escape mechanisms, are 'personalized' oncolytic viruses that encode one or more tumor-specific transgenes. Herein, positive therapeutic effects for MY-NEOVAX™, personalized neoantigen-enhanced oncolytic adenoviruses, are described for two heavily pretreated end-stage patients, one with high-grade metastatic neuroendocrine carcinoma of the pancreas and the other with colorectal cancer metastatic to the brain, liver and lungs. To date, treatment benefit has exceeded 12 months without dose-limiting toxicities or related serious adverse events and with documented radiologic stabilization and improved performance status

Brief report: RRx-001 is a c-Myc inhibitor that targets cancer stem cells.

The goal of anticancer therapy is to selectively eradicate all malignant cells. Unfortunately for the majority of patients with metastatic disease, this goal is consistently thwarted by the nearly inevitable development of therapeutic resistance; the main driver of therapeutic resistance is a minority subpopulation of cancer cells called cancer stem cells (CSCs) whose mitotic quiescence essentially renders them non-eradicable. The Wnt signaling pathway has been widely implicated as a regulator of CSCs and, therefore, its inhibition is thought to result in a reversal of therapeutic resistance via loss of stem cell properties. RRx-001 is a minimally toxic redox-active epi-immunotherapeutic anticancer agent in Phase III clinical trials that sensitizes tumors to radiation and cytotoxic chemotherapies. In this article, as a potential mechanism for its radio- and chemosensitizing activity, we report that RRx-001 targets CD133 + /CD44 + cancer stem cells from three colon cancer cell-lines, HT-29, Caco-2, and HCT116, and inhibits Wnt pathway signalling with downregulation of c-Myc

Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC.

Few therapeutic options are available for T790M-negative non-small cell lung cancer (NSCLC) after failure of primary epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) and chemotherapy. This report presents the case of a 71-year-old Asian female never smoker with EGFR mutated T790M negative non squamous cell lung cancer (NSCLC) pre-treated with the experimental epi-immunotherapeutic agent, RRx-001, that re-responded to single agent carboplatin after failure of platinum doublets, TKIs, pemetrexed and nivolumab. The management of advanced EGFR mutation-positive NSCLC is briefly reviewed herein and the emerging paradigm of episensitization, which contradicts the long-standing and widely accepted tenet about the immutability of resistance and the futility of therapeutic rechallenge, is introduced as a strategy to avert treatment failure and thereby stave off deterioration and death